Edesa Biotech Provides Update For COVID-19 Antibody Trial

Edesa Biotech Inc EDSA issued an update for the Phase 2/3 study evaluating its monoclonal antibody candidate, EB05, as single-dose therapy for hospitalized COVID-19 patients.
Edesa reported that more than 525 subjects had been randomized into the study.
Approximately 35 of these patients have been assigned to an investigation sub-study evaluating EB05 as rescue therapy for patients with critically severe COVID-19 symptoms.
Edesa expects the analysis from third-party statisticians to be completed in the coming weeks.
The company said that the interim analysis would include data from approximately 316 subjects.
EB05 is an experimental monoclonal antibody that Edesa believes could regulate the overactive and dysfunctional immune response associated with Acute Respiratory Distress Syndrome (ARDS).
Price Action: EDSA shares are up 1.71% at $4.76 during the market session on the last check Thursday.